Skip to main content
Tourmaline Bio, Inc. logo

Tourmaline Bio, Inc. — Investor Relations & Filings

Ticker · TRML ISIN · US87410C1045 US Manufacturing
Open in API
Filings indexed 336 across all filing types
Latest filing 2023-09-06 Regulatory Filings
Country US United States of America
Listing US TRML

About Tourmaline Bio, Inc.

https://www.tourmalinebio.com/

Tourmaline Bio, Inc. is a late-stage clinical biotechnology company focused on developing transformative medicines for patients with life-altering inflammatory and immune diseases. The company's lead asset is pacibekitug, a monoclonal antibody that targets the interleukin-6 (IL-6) cytokine, a key driver of inflammation. Pacibekitug is being developed as a potential treatment for a range of conditions, with a primary focus on atherosclerotic cardiovascular disease (ASCVD) and other severe autoimmune and inflammatory disorders, aiming to establish a new standard of care in areas with high unmet medical need.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2023
Regulatory Filings
2023-09-06 English
425 Filing
Merger & Acquisition Classification · 95% confidence The document is filed pursuant to Rule 425 under the Securities Act of 1933 and Rule 14a-12 under the Securities Exchange Act of 1934, indicating it is related to a merger transaction. It discusses the proposed merger between Talaris Therapeutics and Tourmaline Bio, including details about the merger agreement and related communications. The document references a Form S-4 registration statement and proxy statement that will be filed with the SEC, which are typical for merger-related filings. The content includes a press release about FDA clearance for a drug candidate, but the primary purpose is to communicate information related to the merger transaction. Rule 425 filings are specifically used for merger communications and announcements. Therefore, this document is best classified under Merger & Acquisition (MA). The document length (10,360 characters) and detailed content support that this is a substantive filing rather than a brief announcement or solicitation material alone.
2023-08-28 English
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a detailed response letter from a company and its legal counsel to the SEC staff comments regarding a Registration Statement on Form S-4. The Form S-4 is used for securities issued in connection with mergers and acquisitions. The letter addresses specific SEC comments on disclosures related to a merger transaction, including financial advisor opinions, merger background, tax consequences, and other merger-related disclosures. This is not the registration statement itself but a correspondence responding to SEC comments on the filing. Such correspondence is typically classified as a Regulatory Filing (RNS) because it is a regulatory communication that does not itself constitute the primary report or registration statement but is part of the regulatory review process.
2023-08-25 English
S-4/A
Merger & Acquisition Classification · 100% confidence The document is a Form S-4/A, which is an amendment to a registration statement filed with the SEC under the Securities Act of 1933. It relates to a proposed merger between Talaris Therapeutics, Inc. and Tourmaline Bio, Inc. The text includes detailed descriptions of the merger agreement, exchange ratios, treatment of equity awards, and financing arrangements related to the merger. The presence of the Form S-4 and the detailed merger terms indicate this is a filing related to merger and acquisition activity. It is not an annual report, earnings release, or other financial report, but a regulatory filing specifically for a merger transaction. Therefore, the appropriate classification is Merger & Acquisition (MA). The document length and content confirm it is the actual filing, not just an announcement or proxy statement.
2023-08-25 English
Regulatory Filings 2023
Regulatory Filings
2023-08-17 English
Regulatory Filings 2023
Regulatory Filings
2023-08-16 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.